Repurposed drug studies on the primary prevention of SARS-CoV-2 infection during the pandemic: systematic review and meta-analysis

Repurposed drug studies on the primary prevention of SARS-CoV-2 infection during the pandemic: systematic review and meta-analysis

Objective Current evidence on the effectiveness of SARS-CoV-2 prophylaxis is inconclusive. We aimed to systematically evaluate published studies on repurposed drugs for the prevention of laboratory-confirmed SARS-CoV-2 infection and/or COVID-19 among healthy adults.Design Systematic review.Eligibili...

Full description

Bibliographic Details
Main Authors:	Judith M Vonk, Eelko Hak, Katrien Oude Rengerink, Hubert G M Niesters, Debbie van Baarle, Maarten J Bijlsma, Guiling Zhou, Stefan Verweij, Stijn de Vos, Anna Maria Gerdina Pasmooij, Peter Mol
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2023-11-01
Series:	BMJ Open Respiratory Research
Online Access:	https://bmjopenrespres.bmj.com/content/10/1/e001674.full

Similar Items

Community Use of Repurposed Drugs Before and During COVID-19 Pandemic in the Netherlands: An Interrupted Time-Series Analysis
by: Zhou G, et al.
Published: (2023-09-01)

The effect of adherence to statin therapy on cardiovascular mortality: quantification of unmeasured bias using falsification end-points
by: Maarten J. Bijlsma, et al.
Published: (2016-04-01)

Association between Incidence of Prescriptions for Alzheimer’s Disease and Beta-Adrenoceptor Antagonists: A Prescription Sequence Symmetry Analysis
by: Ali Alghamdi, et al.
Published: (2023-12-01)

Drug repurposing for rare: progress and opportunities for the rare disease community
by: Anneliene Hechtelt Jonker, et al.
Published: (2024-01-01)

A full-document analysis of the semantic relation between European Public Assessment Reports and EMA guidelines using a BERT language model
by: Erik Bergman, et al.
Published: (2023-01-01)

The Association between Deductibles and Cardiovascular Medication Adherence: A Retrospective Inception Cohort Study
by: Dennis Steenhuis, et al.
Published: (2023-11-01)

Risk factors for drug-treated major adverse cardio-cerebrovascular events in patients on primary preventive statin therapy: A retrospective cohort study
by: Dennis Steenhuis, et al.
Published: (2023-08-01)

Tailoring Type II Diabetes Treatment: Investigating the Effect of 5-HTT Polymorphisms on HbA1c Levels after Metformin Initiation
by: Taichi Ochi, et al.
Published: (2024-01-01)

Long-term comparative effectiveness of antihypertensive monotherapies in primary prevention of cardiovascular events: a population-based retrospective inception cohort study in the Netherlands
by: Xuechun Li, et al.
Published: (2023-08-01)

Rapamycin: Drug Repurposing in SARS-CoV-2 Infection
by: Jiri Patocka, et al.
Published: (2021-03-01)

Identification of Doxorubicin as Repurposing Inhibitory Drug for MERS-CoV PLpro
by: Ahmed L. Alaofi, et al.
Published: (2022-11-01)

Improved and optimized drug repurposing for the SARS-CoV-2 pandemic.
by: Sarel Cohen, et al.
Published: (2023-01-01)

Humoral and cellular immune responses after COVID-19 vaccination of lung transplant recipients and patients on the waiting list: a 6-month follow-up
by: Rogier A. S. Hoek, et al.
Published: (2024-01-01)

Editorial: Role of human leukocyte antigens and killer cell immunoglobulin-like receptors in viral infections
by: Jelle de Wit, et al.
Published: (2016-07-01)

Repurposing Therapeutics for Potential Treatment of SARS-CoV-2: A Review
by: Jennifer Santos, et al.
Published: (2020-06-01)

Repurposing and computational design of PARP inhibitors as SARS-CoV-2 inhibitors
by: Shailima Rampogu, et al.
Published: (2023-06-01)

Repurposing potential of posaconazole and grazoprevir as inhibitors of SARS-CoV-2 helicase
by: Syed Hani Abidi, et al.
Published: (2021-05-01)

Modeling of SARS-CoV-2 Treatment Effects for Informed Drug Repurposing
by: Charlotte Kern, et al.
Published: (2021-03-01)

Repurposing of approved drugs with potential to interact with SARS-CoV-2 receptor
by: Tamim Ahsan, et al.
Published: (2021-07-01)

Repurposing of Drugs for SARS-CoV-2 Using Inverse Docking Fingerprints
by: Marko Jukič, et al.
Published: (2021-12-01)

A narrative review of estimands in drug development and regulatory evaluation: old wine in new barrels?
by: M. Mitroiu, et al.
Published: (2020-07-01)

Drug Repurposing of the Alcohol Abuse Medication Disulfiram as an Anti-Parasitic Agent
by: Debbie-Ann Shirley, et al.
Published: (2021-03-01)

COVID or no COVID: Interpreting inconclusive SARS-CoV-2 qPCR results in different populations and platforms
by: Christien Rondaan, et al.
Published: (2023-06-01)

Repurposing the Ladder
by: Rohin Bhatt, et al.
Published: (2021-05-01)

Drug Repurposing, a Fast-Track Approach to Develop Effective Treatments for Glioblastoma
by: Ioannis Ntafoulis, et al.
Published: (2022-07-01)

New Approaches and Repurposed Antiviral Drugs for the Treatment of the SARS-CoV-2 Infection
by: Luana Vittoria Bauso, et al.
Published: (2021-05-01)

Targeting the Spike: Repurposing Mithramycin and Dihydroergotamine to Block SARS-CoV‑2 Infection
by: Soledad Stagnoli, et al.
Published: (2023-11-01)

Repurposing CRISPR/Cas to Discover SARS‐CoV‐2 Detecting and Neutralizing Aptamers
by: Ju Zhang, et al.
Published: (2023-08-01)

Editorial: Development/repurposing of drugs to tackle the multiple variants of SARS-CoV-2
by: Dinorah Gambino
Published: (2023-02-01)

Computational repurposing of asthma drugs as potential inhibitors of SARS-CoV-2 Mpro
by: A. Hussain, et al.
Published: (2022-04-01)

Exploring the SARS-CoV-2 virus-host-drug interactome for drug repurposing
by: Sepideh Sadegh, et al.
Published: (2020-07-01)

Repurposing Fragile X Drugs to Inhibit SARS-CoV-2 Viral Reproduction
by: Cara J. Westmark, et al.
Published: (2020-08-01)

Artificial intelligence-driven drug repurposing and structural biology for SARS-CoV-2
by: Kartikay Prasad, et al.
Published: (2021-01-01)

What Should Be Learned From Repurposed Antivirals Against SARS-CoV-2?
by: Miguel Angel Martinez
Published: (2022-02-01)

Correction to “Targeting the Spike: Repurposing Mithramycin and Dihydroergotamine to Block SARS-CoV‑2 Infection”
by: Soledad Stagnoli, et al.
Published: (2024-01-01)

A comparative analysis of remdesivir and other repurposed antivirals against SARS‐CoV‐2
by: Alexander Simonis, et al.
Published: (2021-01-01)

Blockers of the SARS-CoV-2 3a Channel Identified by Targeted Drug Repurposing
by: Prabhat Pratap Singh Tomar, et al.
Published: (2021-03-01)

Repurposing of Plasminogen: An Orphan Medicinal Product Suitable for SARS-CoV-2 Inhalable Therapeutics
by: Anna Maria Piras, et al.
Published: (2020-11-01)

Repurposing of Four Drugs as Anti-SARS-CoV-2 Agents and Their Interactions with Protein Targets
by: Luis C. Vesga, et al.
Published: (2022-04-01)

Multi-Targeted Approaches and Drug Repurposing Reveal Possible SARS-CoV-2 Inhibitors
by: Khalid Mashay Alanazi, et al.
Published: (2021-12-01)